Literature DB >> 15619217

Renal cell carcinoma in South Korea: a multicenter study.

Haeryoung Kim1, Nam Hoon Cho, Dong-Sug Kim, Young-Mi Kwon, Eun Kyung Kim, Seo Hee Rha, Yong Wook Park, Jung Weon Shim, Sang Sook Lee, Shi Nae Lee, Juhie Lee, Jin Sook Lee, Tae-Jin Lee, Soo Jin Jung, Soon-Hee Jung, Jin Haeng Chung, Hyun Yee Cho, Hee Jae Joo, Yeong-Jin Choi, Chan Choi, Woon Sup Han, Bang Hur, Jae Y Ro.   

Abstract

The incidence of renal cell carcinoma (RCC) in South Korea is steadily becoming similar to that in Western countries. This study summarizes the results of a 3-year multicenter survey of RCC in South Korea, conducted by the Korean Genitourinary Pathology Study Group. A total of 795 cases of RCC were collected from 20 institutes between 1995 and 1997, including 686 clear cell RCCs (86.3%), 58 papillary RCCS (7.30%), 49 chromphobe RCCs (6.16%), and 2 collecting duct RCCs (0.25%). At least 5 years of follow-up was available for 627 clear cell, 54 papillary, and 49 chromophobe RCCs. All subtypes presented most frequently with stage T3aN0M0 at the time of operation, and papillary RCCs demonstrated more frequent lymph node metastasis. Overall survival was not significantly related to the histological subtype (clear cell vs papillary, P = 0.8651; clear cell vs chromophobe, P = 0.0584; papillary vs chromophobe, P = 0.0743). For clear cell RCCs, statistically significant associations were found between overall survival and sex (P = 0.0153), multiplicity (P = 0.0461), necrosis (P = 0.0191), age, sarcomatoid change, TNM stage, nuclear grade, and modality of treatment (all P <0.0001). Overall survival was significantly associated with tumor size (P = 0.0307), nuclear grade (P = 0.0235), multiplicity, sarcomatoid change, and TNM stage (all P <0.0001) for papillary RCCs and with the presence of sarcomatoid change (P = 0.0281), nuclear grade (P = 0.0015), treatment modality (P = 0.0328), and TNM stage (P <0.0001) for chromophobe RCCs. Age (P = 0.0125), nodal stage (P = 0.0010), and treatment modality (P = 0.0001) were significant independent prognostic indicators for clear cell RCC on multivariate analysis. This is the first multicenter study of RCC in South Korea, demonstrating the general patterns and prognostic factors of Korean RCCs.

Entities:  

Mesh:

Year:  2004        PMID: 15619217     DOI: 10.1016/j.humpath.2004.06.011

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Answer to comment on manuscript "Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients".

Authors:  H Borgmann; M Musquera; M May; S D Brookman-May
Journal:  World J Urol       Date:  2018-07-18       Impact factor: 4.226

2.  Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients.

Authors:  H Borgmann; M Musquera; A Haferkamp; A Vilaseca; T Klatte; S F Shariat; A Scavuzzo; M A Jimenez Rios; I Wolff; U Capitanio; P Dell'Oglio; L M Krabbe; E Herrmann; T Ecke; D Vergho; N Huck; N Wagener; S Pahernik; S Zastrow; M Wirth; C Surcel; C Mirvald; K Prochazkova; G Hutterer; R Zigeuner; L Cindolo; M Hora; C G Stief; M May; S D Brookman-May
Journal:  World J Urol       Date:  2017-08-23       Impact factor: 4.226

3.  Expression of CC chemokine receptor 5 in clear cell renal cell carcinoma and its clinical significance.

Authors:  Koo Han Yoo; Dong-Gi Lee; Kyu Yeoun Won; Sung-Jig Lim; Yong-Koo Park; Sung-Goo Chang
Journal:  Oncol Lett       Date:  2015-03-17       Impact factor: 2.967

4.  [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].

Authors:  S Waalkes; F C Roos; H Eggers; S Schumacher; M Janssen; G Wegener; J W Thüroff; R Hofmann; M Schrader; M A Kuczyk; A J Schrader
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

5.  Brain metastasis of a papillary renal cell carcinoma, identified as type 2.

Authors:  Masanori Hasegawa; Eiji Kikuchi; Yota Yasumizu; Seiya Hattori; Toshikazu Takeda; Shinya Morita; Takeo Kosaka; Akira Miyajima; Takashi Horiguchi; Shuji Mikami; Mototsugu Oya
Journal:  Int J Clin Oncol       Date:  2009-07-11       Impact factor: 3.402

6.  Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.

Authors:  Sandra Steffens; Frederik C Roos; Martin Janssen; Frank Becker; Julie Steinestel; Mahmoud Abbas; Konrad Steinestel; Gerd Wegener; Stefan Siemer; Joachim W Thüroff; Rainer Hofmann; Michael Stöckle; Mark Schrader; Arndt Hartmann; Kerstin Junker; Markus A Kuczyk; Andres J Schrader
Journal:  Virchows Arch       Date:  2014-09-02       Impact factor: 4.064

7.  Incidence and long-term prognosis of papillary renal cell carcinoma.

Authors:  A J Schrader; S Rauer-Bruening; P J Olbert; A Hegele; J Rustemeier; N Timmesfeld; Z Varga; R Hofmann
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-21       Impact factor: 4.553

8.  Deficiency of MSH2 expression is associated with clear cell renal cell carcinoma.

Authors:  Koo Han Yoo; Kyu Yeoun Won; Sung-Jig Lim; Yong-Koo Park; Sung-Goo Chang
Journal:  Oncol Lett       Date:  2014-08-26       Impact factor: 2.967

9.  Sub-typing of renal cell tumours; contribution of ancillary techniques.

Authors:  Dinesh Pradhan; Nandita Kakkar; Amanjit Bal; Shrawan Kumar Singh; Kusum Joshi
Journal:  Diagn Pathol       Date:  2009-06-28       Impact factor: 2.644

10.  A multi-institutional study on histopathological characteristics of surgically treated renal tumors: the importance of tumor size.

Authors:  Sun Il Kim; Yeung Deuk Choi; Se Joong Kim; Byung Ha Chung; Do Hwan Seong; Chun Il Kim; Sang Hyeon Cheon; Jin Seon Cho; Yun Seob Song; Young Sig Kim; In Rae Cho; Dong Hyeon Lee; Ki Hak Song; Hong Sup Kim; Joong Shik Lee; Won Jae Yang; Sung Joon Hong
Journal:  Yonsei Med J       Date:  2008-08-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.